deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02107937

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma

Sponsor: SOTIO a.s.

Conditions Ovarian Epithelial Cancer Ovarian Neoplasms
Interventions DCVAC/OvCa sequentially chemotherapy DCVAC/OvCa with Standard of Care Standard of Care
Updated 15 times since 2017 Last updated: May 3, 2022 Started: Nov 30, 2013 Primary completion: Nov 30, 2020 Completion: Nov 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02107937, this PHASE2 trial focuses on Ovarian Epithelial Cancer and Ovarian Neoplasms and remains completed. Sponsored by SOTIO a.s., it has been updated 15 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Apr 2020 · 16 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Sep 2023 · 15 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2022 — Sep 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Nov 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. May 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2018 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  8. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  9. Aug 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SOTIO a.s.
Data source: Sotio Biotech Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations